A phase 1/2 trial multi-center, open-label, dose escalation and expansion study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with malignant solid tumors.

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

09 Jul 2024 New trial record
08 Jul 2024 According to an Immorna Biotherapeutics media release, company announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for JCXH-211 intravenous (IV).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com